GEN Exclusives

More »

GEN News Highlights

More »
Feb 15, 2007

Cepheid Procures Sangtec Molecular Diagnostics

  • Cepheid purchased Sangtec Molecular Diagnostics for approximately $27 million in cash. Sangtec, based in Bromma, Sweden, develops and manufactures PCR-based molecular diagnostics products.

    "The acquisition of Sangtec immediately brings Cepheid three key strategic benefits," points out Cepheid CEO, John Bishop. “First, Sangtec currently has a relatively complete line of products for potential use in managing infections of immunocompromised patients. Second, Sangtec has a very strong R&D team experienced in developing real-time PCR-based products, which will enable Cepheid to more expeditiously expand its clinical test product menu. Third, Sangtec has an accomplished manufacturing team noted for its ability to produce high-quality products. This team will provide Cepheid with an established reagent-manufacturing base in Europe.”

    Cepheid plans to integrate the Sangtec affigene® family of real-time PCR molecular diagnostic kits targeted at the immunocompromised market into its existing European and U.S. portfolio of in vitro diagnostic products. The expanded line will include assay kits for cytomegalovirus, Epstein-Barr virus, herpes simplex virus 1 and 2, hepatitis B virus, varicella zoster virus, BK virus, and aspergillus.

    Sangtec currently has 59 employees and had revenues in 2006 of approximately $8 million.

    Cepheid predicts that the acquisition will be slightly dilutive to operating income for the first quarter following the acquisition but should be slightly accretive to operating income for the balance of the year, making a neutral impact on operating income for 2007 neutral.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Value-Pricing Cancer Drugs

Do you think all new cancer drugs awaiting approval should undergo value-pricing?

More »